Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support clinical development through regulatory approval and commercialization Immuron has U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application IND 32095 is Immuron's Investigational new drug (IND) application for clinical development of IMM-529 as a product to specifically prevent or treat Clostridioides difficile infection (CDI) MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has engaged Pullan Consulting to provide business development services to assist in securing a strategic partnership for IMM-529. Pullan Consulting is a highly regarded life sciences advisory firm with a strong track record of executing between five and twelve partnering transactions annually over the past 20 years.
Immuron Limited(IMRN)Earnings, Financials & Key Ratios
IMRN•NASDAQ
$1.12
Price updated Jul 6, 2026
AboutImmuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.Show more
- Revenue$7M+48.6%
- EBITDA-$5M+8.0%
- Net Income-$5M+24.8%
- EPS (Diluted)-0.90+26.2%
- Gross Margin65.39%-3.9%
- EBITDA Margin-72.66%+38.1%
- Operating Margin-73.34%+38.0%
- Net Margin-71.58%+49.4%
- ROE-50.3%-17.2%
IMRN Price & Volume
Immuron Limited (IMRN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Challenge Immuron's Growth Trajectory
Investment Thesis • Updated 2026Q2
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:High clinical funding dependency
Key Thesis Takeaways
- Immuron faces a precarious financial outlook as its core antibody platform struggles to achieve consistent commercial scale, evidenced by a persistent operating loss of $2.3 million in 2026Q2.
- While the company maintains a stable gross margin of 63.4%, the lack of a self-sustaining revenue model necessitates ongoing reliance on capital reserves that have eroded from $18.5 million in 2023Q2 to $10.0 million.
- Investors should monitor the company's ability to manage its clinical trial burn rate, as the current lack of tangible assets and significant accumulated deficit of $83.2 million present substantial long-term solvency risks.
Verdict Logic
the company's inability to generate positive free cash flow, combined with a rapid decline in cash reserves to $10.0 million, suggests that the current capital structure may require further dilutive financing to sustain operations.
IMRN Growth Metrics
Immuron Limited (IMRN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years21.94%
5 Years23.67%
3 Years111.96%
TTM59.55%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM19.91%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM25.13%
Return on Capital
10 Years-62.61%
5 Years-33.55%
3 Years-34.36%
Last Year-50.96%
Latest IMRN News
Recent stock market news and headlines for Immuron Limited (IMRN)
GlobeNewsWire·1 day ago
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering StrategyPeers Comparison
Key metrics vs top competitors for Immuron Limited (IMRN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.12 | $7.67M | -1.80 | 48.63% | -71.58% | -50.3% | — | |
| $80.78 | $9.58B | 31.55 | 37.55% | 23.13% | 126.27% | — | |
| $9.16 | $2.12B | 15.27 | 19.63% | 32.43% | 38.97% | — | |
| $3.41 | $142M | -1002.94 | 10.37% | 52.16% | — | — | |
| $9.35 | $1.54B | 3.68 | 64.69% | -14.73% | — | — | |
| $0.63 | $152.32M | 8.99 | 726.68% | 14.51% | 61.43% | — |
Compare IMRN vs Peers
Immuron Limited (IMRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when IMRN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMRN Frequently Asked Questions
Immuron Limited (IMRN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Immuron Limited's revenue?
Immuron Limited (IMRN) reported $13.0M in revenue for fiscal year 2025. This represents a 2571% increase from $0.5M in 2001.
How fast is Immuron Limited growing?
Immuron Limited (IMRN) grew revenue by 48.6% over the past year. This is strong growth.
Is IMRN profitable?
Immuron Limited (IMRN) reported a net loss of $8.5M for fiscal year 2025.
Dividend & Returns
What is IMRN's return on equity?
Immuron Limited (IMRN) has a return on equity (ROE) of -50.3%. Negative ROE indicates the company is unprofitable.
What is Immuron Limited's free cash flow?
Immuron Limited (IMRN) had negative free cash flow of $9.6M in fiscal year 2025, likely due to heavy capital investments.